Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:AVBP NASDAQ:CRBU NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$24.69+0.6%$24.09$12.21▼$41.31$721.29M-0.2506,266 shs326,863 shsAVBPArriVent BioPharma$18.66-4.4%$22.07$15.47▼$36.37$667.49M1.17238,524 shs304,192 shsCRBUCaribou Biosciences$1.95-3.9%$1.51$0.66▼$3.00$188.80M2.551.94 million shs1.25 million shsVIRVir Biotechnology$5.03-0.8%$5.30$4.32▼$14.45$700.87M1.181.08 million shs809,884 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+0.57%-8.35%+3.39%+16.52%-29.13%AVBPArriVent BioPharma-4.36%-11.90%-11.56%-12.39%-14.79%CRBUCaribou Biosciences-3.94%-14.47%+42.34%+121.59%-15.95%VIRVir Biotechnology-0.79%-10.97%-7.37%-18.34%-50.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio2.2134 of 5 stars3.40.00.00.03.22.50.6AVBPArriVent BioPharma2.0202 of 5 stars4.60.00.00.01.90.80.0CRBUCaribou Biosciences2.4417 of 5 stars3.54.00.00.00.61.70.6VIRVir Biotechnology2.8821 of 5 stars3.41.00.00.02.43.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$47.1390.87% UpsideAVBPArriVent BioPharma 3.14Buy$39.29110.53% UpsideCRBUCaribou Biosciences 3.00Buy$8.50335.90% UpsideVIRVir Biotechnology 2.88Moderate Buy$30.25501.39% UpsideCurrent Analyst Ratings BreakdownLatest CRBU, ANAB, AVBP, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $80.007/22/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.007/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$12.007/10/2025AVBPArriVent BioPharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$33.006/24/2025AVBPArriVent BioPharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$39.00 ➝ $44.006/24/2025AVBPArriVent BioPharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.006/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M7.95N/AN/A$2.33 per share10.60AVBPArriVent BioPharmaN/AN/AN/AN/A$7.65 per shareN/ACRBUCaribou Biosciences$9.99M18.15N/AN/A$2.79 per share0.70VIRVir Biotechnology$74.21M9.37N/AN/A$8.35 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)AVBPArriVent BioPharma-$80.49M-$3.77N/AN/AN/AN/A-49.21%-46.61%8/13/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%8/6/2025 (Confirmed)Latest CRBU, ANAB, AVBP, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025AVBPArriVent BioPharma-$0.70N/AN/AN/AN/AN/A8/6/2025Q2 2025VIRVir Biotechnology-$0.83N/AN/AN/A$2.38 millionN/A8/5/2025Q2 2025CRBUCaribou Biosciences-$0.40N/AN/AN/AN/AN/A8/4/2025Q2 2025ANABAnaptysBio-$1.47N/AN/AN/A$11.55 millionN/A5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.258.25AVBPArriVent BioPharmaN/A14.3414.34CRBUCaribou BiosciencesN/A7.637.63VIRVir BiotechnologyN/A6.796.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AAVBPArriVent BioPharma9.48%CRBUCaribou Biosciences77.51%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%AVBPArriVent BioPharma18.58%CRBUCaribou Biosciences8.28%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million19.54 millionOptionableAVBPArriVent BioPharma4034.21 million27.86 millionN/ACRBUCaribou Biosciences10093.00 million85.30 millionOptionableVIRVir Biotechnology580138.24 million116.12 millionOptionableCRBU, ANAB, AVBP, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 1 at 3:10 AM | marketbeat.comVir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical SetbacksJuly 31 at 7:23 PM | genengnews.comGVir Biotechnology (VIR) Projected to Post Quarterly Earnings on WednesdayJuly 31 at 9:31 AM | marketbeat.comVir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis DeltaJuly 31 at 8:05 AM | businesswire.comAllianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)July 31 at 4:40 AM | marketbeat.comVictory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)July 31 at 4:33 AM | marketbeat.comVir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseJuly 30 at 11:07 AM | zacks.comVir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumoursJuly 26, 2025 | pharmabiz.comPFirst subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525July 25, 2025 | finance.yahoo.comVir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid TumorsJuly 24, 2025 | businesswire.comVir Biotechnology: Hep B And Cancer Projects March OnJuly 23, 2025 | seekingalpha.comVir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025July 22, 2025 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in StockJuly 18, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in StockJuly 18, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of StockJuly 18, 2025 | insidertrades.comInvenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory BoardJuly 14, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationJuly 12, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James FinancialJuly 11, 2025 | marketbeat.comVir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?July 10, 2025 | zacks.comVir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?July 9, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBU, ANAB, AVBP, and VIR Company DescriptionsAnaptysBio NASDAQ:ANAB$24.69 +0.14 (+0.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.68 -0.01 (-0.02%) As of 08/1/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.ArriVent BioPharma NASDAQ:AVBP$18.66 -0.85 (-4.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.67 +0.01 (+0.05%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Caribou Biosciences NASDAQ:CRBU$1.95 -0.08 (-3.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Vir Biotechnology NASDAQ:VIR$5.03 -0.04 (-0.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.17 +0.14 (+2.86%) As of 08/1/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
